DE69918089D1 - Btk inhibitoren und verfahren zur identifizierung und verwendung - Google Patents

Btk inhibitoren und verfahren zur identifizierung und verwendung

Info

Publication number
DE69918089D1
DE69918089D1 DE69918089T DE69918089T DE69918089D1 DE 69918089 D1 DE69918089 D1 DE 69918089D1 DE 69918089 T DE69918089 T DE 69918089T DE 69918089 T DE69918089 T DE 69918089T DE 69918089 D1 DE69918089 D1 DE 69918089D1
Authority
DE
Germany
Prior art keywords
identification
btk inhibitors
inhibitors
btk
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69918089T
Other languages
English (en)
Other versions
DE69918089T2 (de
Inventor
Fatih M Uckun
Yaguo Zheng
Sutapa Ghosh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Parker Hughes Institute
Original Assignee
Parker Hughes Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/273,191 external-priority patent/US6303652B1/en
Application filed by Parker Hughes Institute filed Critical Parker Hughes Institute
Publication of DE69918089D1 publication Critical patent/DE69918089D1/de
Application granted granted Critical
Publication of DE69918089T2 publication Critical patent/DE69918089T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
DE69918089T 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung Expired - Fee Related DE69918089T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8209498P 1998-04-17 1998-04-17
US82094P 1998-04-17
US273191 1999-03-19
US09/273,191 US6303652B1 (en) 1998-08-21 1999-03-19 BTK inhibitors and methods for their identification and use
PCT/US1999/008556 WO1999054286A2 (en) 1998-04-17 1999-04-19 Btk inhibitors and methods for their identification and use

Publications (2)

Publication Number Publication Date
DE69918089D1 true DE69918089D1 (de) 2004-07-22
DE69918089T2 DE69918089T2 (de) 2005-07-14

Family

ID=26767041

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69918089T Expired - Fee Related DE69918089T2 (de) 1998-04-17 1999-04-19 Btk inhibitoren und verfahren zur identifizierung und verwendung

Country Status (13)

Country Link
EP (1) EP1071658B1 (de)
JP (1) JP2002512216A (de)
KR (1) KR20010042804A (de)
AT (1) ATE269295T1 (de)
AU (1) AU3653099A (de)
CA (1) CA2328962A1 (de)
DE (1) DE69918089T2 (de)
ES (1) ES2222705T3 (de)
HU (1) HUP0102661A2 (de)
IL (1) IL139080A0 (de)
MX (1) MXPA00010150A (de)
NO (1) NO20005224L (de)
WO (1) WO1999054286A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO2002034251A1 (en) * 2000-10-20 2002-05-02 Parker Hughes Institute Treatment of asthma with lfm analogues
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
DE60008574T2 (de) 1999-11-05 2009-10-01 Cytovia, Inc., San Diego Substituierte 4H-Chromene und Analoga als Caspase-Aktivatoren und Apoptose-Induktoren und deren Verwendung
JP2003516351A (ja) * 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
HUP0303656A3 (en) * 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
DE60221104T2 (de) * 2001-03-07 2008-03-13 TELIK, INC., Palo Alto Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
EP1377291A2 (de) * 2001-03-13 2004-01-07 Protagen AG 1-butansäuderivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
EP1392283A4 (de) * 2001-05-16 2004-10-20 Cytovia Inc Substituierte cumarine und chinoline als caspase-aktivatoren
JP4593880B2 (ja) 2001-05-16 2010-12-08 サイトビア インコーポレイテッド カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された４ｈ−クロメンおよび類似体、並びにその使用方法
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
AU2002329000A1 (en) * 2001-09-24 2003-04-07 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2484702A1 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1534666A1 (de) 2002-09-06 2005-06-01 Schebo Biotech AG Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
CA2584655A1 (en) * 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
EP2270200A3 (de) * 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinasehemmer und Verfahren zur Verwendung und Identifizierung von Kinasehemmern
PT2530083T (pt) 2006-09-22 2016-08-01 Pharmacyclics Llc Inibidores de tirosina cinase de bruton
SI2134374T1 (sl) * 2007-03-14 2014-03-31 Bionsil S.R.L. In Liquidazione Inhibitorji btk za rabo pri zdravljenju na kemoterapevtska zdravila rezistentnih epitelijskih tumorjev
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
JP5479105B2 (ja) * 2007-11-05 2014-04-23 国立大学法人佐賀大学 新規ユビキリン結合性小分子
CA2724861A1 (en) 2008-06-05 2009-12-10 Alembic Limited A process for preparing teriflunomide
US20110224235A1 (en) 2008-07-16 2011-09-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
MX2012011504A (es) 2010-04-05 2013-01-18 Mannkind Corp Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
EP2877598A1 (de) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutationen im zusammenhang mit der resistenz gegenüber hemmern der bruton-tyrosinkinase (btk)
EP2920180A4 (de) 2012-11-15 2016-04-13 Pharmacyclics Inc Pyrrolopyrimidinverbindungen als kinaseinhibitoren
EP2925858B1 (de) 2012-11-28 2019-05-15 Corning Incorporated Zellenkulturmedium für erhöhte hepatozytenfunktion
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
JP6118453B2 (ja) * 2013-04-02 2017-04-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼの阻害剤
EP2832358A1 (de) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmazeutisches Kit zur Verwendung bei der Behandlung von Darm- und kolorektalem Krebs
WO2015017812A1 (en) 2013-08-02 2015-02-05 Pharmacyclics, Inc. Methods for the treatment of solid tumors
JP6429292B2 (ja) 2013-08-12 2018-11-28 ファーマサイクリックス エルエルシー Ｈｅｒ２増幅性癌の処置のための方法
CR20160203A (es) 2013-09-30 2016-08-31 Pharmacyclics Llc Inhibidores de tirosina cinasa de bruton
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AU2014361800B2 (en) 2013-12-13 2020-05-07 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
CA2959602A1 (en) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN106573002A (zh) 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
CA2965178C (en) 2014-10-22 2023-09-26 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
PL3436447T3 (pl) 2016-03-31 2021-12-27 Takeda Pharmaceutical Company Limited Kompleksy triazolonu izochinolinylowego
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
MX2021009863A (es) 2019-03-21 2021-11-12 Onxeo Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
EP4054579A1 (de) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur behandlung von krebsarten, die resistenz gegen kinase-inhibitoren erworben haben
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555685A1 (de) * 1975-12-11 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
RU2142937C1 (ru) * 1990-05-18 1999-12-20 Хехст АГ Амиды органических кислот, способ их получения и фармацевтическая композиция
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
US5723631A (en) * 1992-12-23 1998-03-03 Smithkline Beecham Corporation Coumarin derivatives as retroviral inhibitors
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5489697A (en) * 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina

Also Published As

Publication number Publication date
EP1071658A2 (de) 2001-01-31
NO20005224D0 (no) 2000-10-17
NO20005224L (no) 2000-12-18
WO1999054286A3 (en) 2000-05-04
DE69918089T2 (de) 2005-07-14
CA2328962A1 (en) 1999-10-28
EP1071658B1 (de) 2004-06-16
WO1999054286A2 (en) 1999-10-28
KR20010042804A (ko) 2001-05-25
ATE269295T1 (de) 2004-07-15
HUP0102661A2 (hu) 2001-11-28
JP2002512216A (ja) 2002-04-23
ES2222705T3 (es) 2005-02-01
IL139080A0 (en) 2001-11-25
MXPA00010150A (es) 2002-05-14
AU3653099A (en) 1999-11-08

Similar Documents

Publication Publication Date Title
DE69918089D1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
DE60007095T2 (de) Calanolide zur hemmung von btk
DE60125715D1 (de) Verfahren und testsysteme zur identifizierung von elite event gat-zm1 in biologischen proben
DE60214946D1 (de) Verfahren und System zur Bereitstellung von Informationen
ATE471374T1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE467301T1 (de) Verfahren und vorrichtung für gleichrangigen diensten
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
ATE547101T1 (de) Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
DE60038328D1 (de) Gerät, Verfahren und Medium zur Informationsverarbeitung
DE602004018714D1 (de) Verfahren zur Bereitstellung von zweiteiligen, selbstklebenden Dentalmassen
EP1565230A4 (de) Materialzusammensetzungen und verwandtesysteme und verfahren zur behandlung von herzerkrankungen
ATE309196T1 (de) Verfahren zur herstellung von 3-aryloxy-3- arylpropylamine und deren zwischenprodukte
ATE458191T1 (de) Verfahren zur selektion von partikeln
DE60309647D1 (de) System und Verfahren zur gesicherten Behandlung von Kontrollinformationen
DE60210265D1 (de) Verfahren und zwischenprodukte zur herstellung von 4-aminochinolin-cetp-inhibitoren
EP1700120A4 (de) Marker für neuromyelitis optica
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DE50203510D1 (de) Verfahren zur erkennung und identifizierung von objekten
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
DE69925482D1 (de) Verfahren, einrichtung und gerät zur authentifizierung
DE60023461D1 (de) Verdichter und verfahren zur schmierung des kompressors
DE60315575D1 (de) Verfahren und Vorrichtung zur Untersuchung von Oberflächen
DE60136607D1 (de) System und Verfahren zur Lieferung von Karteninformationen
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE50112874D1 (de) Verfahren und vorrichtung zur darstellung von informationen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee